Navigation Links
Drug Improved Survival in Mice With Cystic Fibrosis
Date:2/19/2010

Protein pathway discovery could lead to new treatments, study suggests

FRIDAY, Feb. 19 (HealthDay News) -- In the search for new treatments for cystic fibrosis, U.S. researchers have identified a defective signaling pathway that contributes to the severity of the inherited lung disease.

Cystic fibrosis causes thick, sticky mucus to build up in the lungs and digestive tract, and is one of the most common potentially lethal genetic diseases in children and young adults.

In the new study, the researchers found that correcting the defective signaling pathway for a protein called peroxisome proliferator-activated receptor-y (PPAR-y) reduced cystic fibrosis symptoms in mice.

"Cystic fibrosis results from a genetic mutation in a channel, or membrane pore, that facilitates the transport of chloride and bicarbonate electrolytes from inside the cell to the spaces outside the cell," lead investigator Dr. Gregory Harmon, of the University of California, San Diego School of Medicine, said in a news release from the school.

"Loss of the cystic fibrosis pore channel results in inflammation and mucus accumulation. It also results in dehydration of the cell surfaces that make up the lining spaces inside the lungs and other affected organs, such as the intestinal tract," he explained.

Working with cells from mice and human cell lines from cystic fibrosis patients, Harmon and his colleagues determined that multiple genes affected by PPAR-y were reduced in cystic fibrosis.

The researchers then treated mice with cystic fibrosis with the drug rosiglitazone (a drug that binds and activates PPAR-y) and found that gene expression was largely normalized and survival improved. Among the other findings:

  • Drug treatment also corrected part of the inflammatory process associated with cystic fibrosis.
  • Deleting PPAR-y in the intestine of mice worsened cystic fibrosis.
  • Activating PPAR-y can increase bicarbonate production in intestinal tissue by increasing the activity of bicarbonate-producing enzymes called carbonic anhydrases.

"For the first time, we are able to use a drug that activates bicarbonate transport without affecting chloride transport, and see improvement in the disease," Harmon said.

The findings, published in the Feb. 14 issue of Nature Medicine, may lead to new treatments for cystic fibrosis.

More information

The Cystic Fibrosis Foundation answers questions about cystic fibrosis.



-- Robert Preidt



SOURCE: University of California, San Diego Health Sciences, news release, Feb. 14, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Small to Mid-Sized Hospitals Turn to Orion Health to Implement Health IT Solutions for Improved Patient Care and Outcomes
2. Medical Transcription Services and EHR Provider MxSecure Launches New Enhanced Website with Goal of Improved Physician Productivity
3. Exercise Success for People Over 50: Reports of Improved Fitness, Circulation and Balance
4. Improved air quality linked to fewer pediatric ear infections
5. Chronic sinusitis patients experience improved quality of life after endoscopic sinus surgery
6. After Tough 2009, Improved Accountability and Consistent Insurance Industry Standards Key in 2010
7. BioProcess International Launches a New and Improved Website for Biopharmaceutical Managers and Scientists
8. IBM Chosen to Build System for Electronic Health Records in Manitoba for Improved Patient Care
9. Parent training key to improved treatment of behavior problems in children with autism
10. United Concordia Dental Redesigns Web Site To Provide Improved Access To Information
11. Parascript Announces AccuDetect 3.0 Computer Aided Detection (CAD) Algorithms With Improved Performance for CAD Vendors and Manufacturers of Mammography Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 18, 2017 , ... ProParagraph Fashion ... Film Studios ’ ProParagraph Fashion Volume 2 for all multi-line FCPX project needs. ... Users can pick and choose from hand-crafted trend-setting designs with smooth animations that ...
(Date:2/17/2017)... CA (PRWEB) , ... February 17, 2017 , ... ... focus on foundational and sustainable systems change designed to further positively impact the ... “The Board of Trustees has long considered it our duty to seriously consider ...
(Date:2/17/2017)... Palos Verdes, CA (PRWEB) , ... February 17, ... ... and emotional flow is Dr. Carol Francis' goals for each and ... Retreat Conference, Dr. Carol Francis will demonstrate five different brainwave tools which help ...
(Date:2/17/2017)... ... February 17, 2017 , ... Program will serve ... Health and the U.S. Soccer Foundation announced today that they have awarded nine ... for Success, the Foundation’s soccer mentoring program, teaches kids the fundamentals of soccer ...
(Date:2/17/2017)... ... 2017 , ... Cancer diagnostics workflow solution provider Inspirata, Inc., ... 22 in San Francisco. As part of the Tri-Conference expo, which is open ... as well as its new precision medicine platform, “Crosswalk Insight: Oncology™.” , Inspirata ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... Feb 17, 2017 Research and Markets has announced ... Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , and Rest of World. Annual estimates ... six-year historic analysis is provided for these markets. Market data and analytics ...
(Date:2/17/2017)... NEW YORK , Feb. 17, 2017   ... other side effects allegedly associated with use of the ... Philadelphia Court of Common Pleas, ... a mass tort program. According to a notice posted ... scheduled to convene a meeting on March 9, 2017 ...
(Date:2/17/2017)... , Feb. 17, 2017   FormFast , ... announced a new partnership with Engage , one ... United States . FormFast will serve as the ... Engage,s implementations with MEDITECH .  ... essential functionality to complement and enhance the electronic health ...
Breaking Medicine Technology: